|
Tercica to Hold 2008 First Quarter Financial Results Conference Call May 12
May 1, 2008
|
7.7 KB |
| |
BRISBANE, Calif., May 01, 2008 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ: TRCA) today announced the Company will release its 2008 first quarter financial results after market close on Monday, May 12, 2008.
Management will host an investment community conference call beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) on Monday, May 12, ...
|
|
|
Tercica to Present at March Investment Conferences
Mar 10, 2008
|
7.8 KB |
| |
BRISBANE, Calif., Mar 10, 2008 (BUSINESS WIRE) -- Tercica, Inc. (Nasdaq: TRCA) today announced that company management will make the following investment community presentations:
-- Cowen & Company 28th Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston on Monday, March 17 at 4:00 p.m. Eastern time (1:00 p.m....
|
|
|
Tercica Announces Changes to Its Board of Directors and Management Team
Feb 29, 2008
|
8.2 KB |
| |
BRISBANE, Calif., Feb 29, 2008 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ:TRCA) today announced that it has named Richard King as President and Chief Operating Officer. Previously, Mr. King was Tercica's Chief Operating Officer. John A. Scarlett, M.D., will remain as the Chief Executive Officer of Tercica. The Company also announced that Ajay Bansal ...
|
|
|
Tercica Reports Fourth Quarter and Year-End 2007 Financial Results
Feb 27, 2008
|
16.7 KB |
| |
BRISBANE, Calif., Feb 27, 2008 (BUSINESS WIRE) -- Tercica, Inc. (Nasdaq: TRCA) today announced financial results for the quarter and year ended December 31, 2007. Net product sales for the quarter ended December 31, 2007 totaled $3.8 million. The net loss for the quarter was $18.7 million, or $0.36 per share, compared to a net loss of $41.0 million...
|
|
|
Tercica to Hold 2007 Fourth Quarter and Year-End Financial Results Conference Call February 27
Feb 20, 2008
|
7.8 KB |
| |
BRISBANE, Calif., Feb 20, 2008 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ:TRCA) today announced the Company will release its 2007 fourth quarter and year-end financial results before market open on Wednesday, February 27, 2008.
Management will host an investment community conference call beginning at 9:00 a.m. Eastern time (6:00 a.m. Pacific time...
|
|
|
Tercica Initiates Phase II Clinical Trial with Next-Generation Growth Hormone Product for the Treatment of Short Stature
Jan 22, 2008
|
10.2 KB |
| |
BRISBANE, Calif., Jan 22, 2008 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ: TRCA) today announced that the Company has begun dosing the first patient in a Phase II clinical study evaluating the combination of Genentech, Inc.'s recombinant human growth hormone Nutropin AQ(R) (somatropin (rDNA origin)) and Tercica's recombinant insulin-like growth facto...
|
|
|
Tercica Reports Third Quarter 2007 Financial Results
Nov 1, 2007
|
15.8 KB |
| |
BRISBANE, Calif., Nov 01, 2007 (BUSINESS WIRE) -- Tercica, Inc. (Nasdaq:TRCA) today announced financial results for the quarter ended September 30, 2007. Net product sales totaled $2.9 million, compared with $316,000 in the third quarter of 2006. Total net revenues for the quarter totaled $23.4 million, including a licensing milestone of $20.3 mill...
|
|
|
Tercica to Hold 2007 Third Quarter Financial Results Conference Call November 1
Oct 30, 2007
|
7.8 KB |
| |
BRISBANE, Calif., Oct 30, 2007 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ:TRCA) today announced the Company will release its 2007 third quarter financial results after market close on Thursday, November 1, 2007.
Management will host an investment community conference call beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) on Thursday, N...
|
|
|
Tercica to Present at November Investment Conferences
Oct 29, 2007
|
7.5 KB |
| |
BRISBANE, Calif., Oct 29, 2007 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ:TRCA) today announced that Company management will make presentations at the following investment conferences in November:
-- Rodman and Renshaw Acumen BioFin 9th Annual Healthcare conference being held at the Palace Hotel in New York on Tuesday, November 6, 2007 at 11:40 a...
|
|
|
Tercica to Present at the BIO Investor Forum on October 10
Oct 2, 2007
|
7.4 KB |
| |
BRISBANE, Calif., Oct 02, 2007 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ:TRCA) today announced that Company management will make an investment community presentation at the BIO Investor Forum at the Palace Hotel in San Francisco. Tercica's presentation will begin at 2:15 p.m. Pacific time (5:15 p.m. Eastern time) on Wednesday, October 10, 2007.
...
|
|
|
Somatuline(R) Depot Receives FDA Marketing Approval for the Treatment of Acromegaly
Aug 30, 2007
|
15.3 KB |
| |
BRISBANE, Calif., Aug 30, 2007 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ:TRCA) today announced that its partner Ipsen (Euronext:IPN) has received notice of approval from the U.S. Food and Drug Administration (FDA) for marketing Somatuline(R) Depot (lanreotide) injection 60, 90 and 120 mg/ml in the United States.
Somatuline(R) Depot is indicated ...
|
|
|
Tercica to Present at the BioCentury and Thomson Financial NewsMakers in the Biotech Industry Conference on September 6
Aug 27, 2007
|
7.5 KB |
| |
BRISBANE, Calif., Aug 27, 2007 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ:TRCA) today announced that Company management will make an investment community presentation at the BioCentury and Thomson Financial NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel & Conference Center in New York. Tercica's presentation will begin...
|
|
|
Tercica Receives Marketing Approval for Increlex in the European Union
Aug 8, 2007
|
11.9 KB |
| |
BRISBANE, Calif., Aug 08, 2007 (BUSINESS WIRE) -- Tercica, Inc. (Nasdaq:TRCA) today announced that the European Commission has granted marketing authorization for Increlex(R) (mecasermin) 10 mg/ml solution for injection. The authorized indication is for the long-term treatment of growth failure in children and adolescents with severe primary insuli...
|
|
|
Tercica Reports Second Quarter 2007 Financial Results
Aug 2, 2007
|
14.4 KB |
| |
BRISBANE, Calif., Aug 02, 2007 (BUSINESS WIRE) -- Tercica, Inc. (Nasdaq:TRCA) today announced financial results for the quarter ended June 30, 2007. Net product sales totaled $2.0 million, compared to $166,000 in the second quarter of 2006. Net loss for the quarter was $12.8 million, or $0.26 per share, compared to a net loss of $14.7 million, or $...
|
|
|
Tercica to Hold 2007 Second Quarter Financial Results Conference Call August 2
Jul 25, 2007
|
7.5 KB |
| |
BRISBANE, Calif., Jul 25, 2007 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ:TRCA) today announced the Company will release its 2007 second quarter financial results after market close on Thursday, August 2, 2007.
Management will host an investment community conference call beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) on Thursday, Au...
|
|
|
Tercica Completes Enrollment of Clinical Trial MS301 Evaluating Treatment with Increlex in Children with Primary IGFD
Jul 19, 2007
|
9.2 KB |
| |
BRISBANE, Calif., Jul 19, 2007 (BUSINESS WIRE) -- Tercica, Inc. (Nasdaq:TRCA) today announced that the Company has completed enrollment of all patients in its MS301 Phase IIIb trial, a study evaluating the efficacy and safety of the current formulation of Increlex(R) (mecasermin (rDNA origin) injection) administered in children with Primary IGFD. I...
|
|
|
Tercica Announces Agreement with Genentech for Worldwide Growth Hormone and IGF-1 Combination Product Development and Commercialization
Jul 10, 2007
|
15.1 KB |
| |
BRISBANE, Calif., Jul 10, 2007 (BUSINESS WIRE) -- Tercica, Inc. (Nasdaq:TRCA) today announced an agreement with Genentech, Inc. for the development, manufacture and worldwide commercialization of two products containing Genentech's recombinant human growth hormone Nutropin AQ(R) (somatropin (rDNA origin)) and Tercica's recombinant insulin-like grow...
|
|
|
Tercica to Present at Investment Conferences
Jul 2, 2007
|
7.5 KB |
| |
BRISBANE, Calif., Jul 02, 2007 (BUSINESS WIRE) -- Tercica, Inc. (NASDAQ:TRCA) today announced that Company management will make an investment community presentation at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference at the Mandarin Oriental Hotel in New York on Wednesday, July 11, 2007 at 4:00 p.m. Eastern time (1:00 p.m. Pacifi...
|
|
|
Tercica Completes Enrollment of Clinical Trial MS308 Evaluating Once-Daily Treatment with Increlex in Children with Primary IGFD
May 31, 2007
|
10.0 KB |
| |
BRISBANE, Calif., May 31, 2007 (BUSINESS WIRE) -- Tercica, Inc. (Nasdaq:TRCA) today announced that the Company has completed enrollment of its MS308 Phase 3b clinical trial, which is a study evaluating the efficacy and safety of the currently approved formulation of Increlex(R) administered as a once-daily injection in children with Primary IGF-1 D...
|
|
|
Tercica Reports Increlex Receives CHMP Positive Opinion for the Treatment of Severe Primary IGF-1 Deficiency
May 25, 2007
|
12.7 KB |
| |
BRISBANE, Calif., May 25, 2007 (BUSINESS WIRE) -- Tercica, Inc. (Nasdaq:TRCA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) adopted a positive opinion recommending marketing authorization for Increlex(R) (mecasermin) 10 mg/ml solution for injection. The indication recommended ...
|
|
|
